# Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy

Study · id `cardio:ct-nct01353469` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01353469](<https://clinicaltrials.gov/study/NCT01353469>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01353469

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 485 participants.

## Technical summary

Registry record NCT01353469. Randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 485 participants (enrolled count; ClinicalTrials.gov record NCT01353469, source copy `cardio:ctgov-nct01353469-2013-02-27`, retrieved 2026-10-26)
- Start date: 2011-05 (registry gives no type) (ClinicalTrials.gov record NCT01353469, source copy `cardio:ctgov-nct01353469-2013-02-27`, retrieved 2026-10-26)
- Primary completion: 2012-11 (actual) (ClinicalTrials.gov record NCT01353469, source copy `cardio:ctgov-nct01353469-2013-02-27`, retrieved 2026-10-26)
- Completion: 2012-11 (actual) (ClinicalTrials.gov record NCT01353469, source copy `cardio:ctgov-nct01353469-2013-02-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01353469, source copy `cardio:ctgov-nct01353469-2013-02-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01353469-2013-02-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
- Acronym: Insuman-C25-CN
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin human/Insuman Comb 25 (HR1799)
- Intervention (Drug): Insulin human/Novolin® 30R
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 47904ab85d5bc3334a338dbbeb5c44e1600da2beeb5ec7dee0d50a934a0faa4b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
